Asia Pacific clinical diagnostics market will grow by 9.8% annually with a total addressable market cap of $257.46 billion over 2022-2031, driven by the rising patient awareness and rising demand for high-quality care amid the COVID-19 pandemic, growing healthcare spend, technological advancement, benefits of clinical diagnostics such as quick test results and easy procedure, increasing prevalence of chronic diseases caused due to sedentary lifestyle such as diabetes, cardiovascular diseases, high blood pressure, lipid disorders, kidney diseases and cancer.
Highlighted with 30 tables and 59 figures, this 114-page report “Asia Pacific Clinical Diagnostics Market 2021-2031 by Test (Lipid Panel, Infectious Disease Testing, Liver Panel, CBC), Product (Instruments, Assay Kits & Reagents, Software & Services), Indication (Cardiovascular, Cancer, Infectious Disease), Patient Gender (Male, Female), Age Group (44 and below, 45-64, 65 and over), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific clinical diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific clinical diagnostics market in every aspect of the classification from perspectives of by Test, Product, Indication, Patient Gender, Age Group, End User, and Country.
Based on Test, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Lipid Panel
• Infectious Disease Testing
• Liver Panel
• Complete Blood Count (CBC)
• Electrolyte Testing
• Renal Panel
• Other Tests
Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Instruments
• Assay Kits & Reagents
• Software & Services
By Indication the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Cardiovascular
• Cancer
• Infectious Disease
• Stroke
• Chronic Lower Respiratory Diseases
• Diabetes
• Other Indications
By Patient Gender the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Male Patients
• Female Patients
By Age Group the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Age 44 and below
• Age 45-64
• Age 65 and over
By End User the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Hospital & Clinics Laboratory
• Diagnostic Laboratory
• Point-of-Care Testing
• Other End Users
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines）
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of key national markets by Test, Product, and Indication, over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
• Abbott Laboratories
• Becton, Dickinson and Company
• BioMerieux SA
• Bio-Rad Laboratories Inc.
• Bio-Reference Laboratories
• Bioscientia Healthcare
• Charles River Laboratories
• Danaher Corporation
• Hoffmann-La Roche AG
• Hologic Inc.
• Qiagen NV
• Siemens Healthcare
• Thermo Fisher Scientific
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
